Scalper1 News
SAN FRANCISCO — Big-cap biotech Celgene (CELG) announced preliminary 2013 results on Monday and raised its long-term guidance, but that fell short of Wall Street’s bullish expectations, driving shares down on the stock market today. At the annual JPMorgan Healthcare Conference in San Francisco, Celgene executives said 2013 revenue totaled $6.5 billion, a bit above analysts’ consensus and up about $1 billion from 2012. Earnings of $3.96 a share Scalper1 News
Scalper1 News